MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16043-16058

  Peng, Yang ^a   Dong, Wen ^a   Lin, Tian Xin ^a   Zhong, Guang Zheng ^a   Liao, Bei ^a   Wang, Bo ^a   Gu, Peng ^a   Huang, Li ^a   Xie, Yun ^a   Lu, Fu Ding ^a   Chen, Xu ^a   Xie, Wei Bin ^a   He, Wang ^a   Wu, Shao Xu ^a   Huang, Jian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Arf; Bladder cancer; Cell proliferation; DMTF1; microRNA 155

Indexed keywords

ARF PROTEIN; MICRORNA 155; PROTEIN P53; DMTF1 PROTEIN, HUMAN; MESSENGER RNA; MICRORNA; MIRN155 MICRORNA, HUMAN; TRANSCRIPTION FACTOR;

AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DMTF1 GENE; FEMALE; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; TUMOR SUPPRESSOR GENE; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BLADDER; BLADDER TUMOR; CANCER GRADING; CANCER STAGING; CELL CYCLE; DRUG SCREENING; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; MIDDLE AGED; MOUSE; NUDE MOUSE; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR RECURRENCE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; URINARY BLADDER; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937853773     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3755     Document Type: Article

References (51)

1. Kato M, Slack FJ. microRNAs: small molecules with big roles -C. elegans to human cancer. BIOL CELL. 2008; 100:71-81.
2. Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. CURR GENOMICS. 2010; 11:537-561.
3. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005; 6:376-385.
4. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. CELL. 2009; 137:1005-1017.
5. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006; 20:515-524.
6. van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. NAT REV CANCER. 2011; 11:644-656.
7. Xiao H, Li H, Yu G, Xiao W, Hu J, Tang K, Zeng J, He W, Zeng G, Ye Z, Xu H. MicroRNA-10b promotes migration and invasion through KLF4 and HOXD10 in human bladder cancer. ONCOL REP. 2014; 31:1832-1838.
8. Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, Benzine T, Madric K, Semmes OJ, Drake R, Esquela-Kerscher A. miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. CELL CYCLE. 2014; 13:227-239.
9. Liu X, Lv XB, Wang XP, Sang Y, Xu S, Hu K, Wu M, Liang Y, Liu P, Tang J, Lu WH, Feng QS, Chen LZ, Qian CN, Bei JX, Kang T, et al. MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. CELL CYCLE. 2012; 11:2495-2506.
10. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. LANCET. 2009; 374:239-249.
11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
12. Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, Dong W, Huang J, Lin T. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. INT J CANCER. 2011; 128:1758-1769.
13. Lin T, Dong W, Huang J, Pan Q, Fan X, Zhang C, Huang L. MicroRNA-143 as a tumor suppressor for bladder cancer. J Urol. 2009; 181:1372-1380.
14. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, Kauppinen S, Ulhoi BP, Kjems J, Borre M, Orntoft TF. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. CANCER RES. 2009; 69:4851-4860.
15. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, Cheng JQ. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. ONCOGENE. 2014; 33:679-689.
16. Li S, Chen T, Zhong Z, Wang Y, Li Y, Zhao X. microRNA-1 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. MOL MED REP. 2012; 5:949-954.
17. Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY, Yan M, Qu QL, Zhu ZG, Liu BY. microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. ONCOL REP. 2012; 27:1960-1966.
18. Qin W, Ren Q, Liu T, Huang Y, Wang J. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS LETT. 2013; 587:1434-1439.
19. Sugiyama T, Frazier DP, Taneja P, Morgan RL, Willingham MC, Inoue K. Role of DMP1 and its future in lung cancer diagnostics. EXPERT REV MOL DIAGN. 2008; 8:435-447.
20. Maglic D, Zhu S, Fry EA, Taneja P, Kai F, Kendig RD, Sugiyama T, Miller LD, Willingham MC, Inoue K. Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. ONCOGENE. 2013; 32:4120-4129.
21. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. CANCER RES. 2005; 65:3980-3985.
22. Saha T, Kar RK, Sa G. Structural and sequential context of p53: A review of experimental and theoretical evidence. Prog Biophys Mol Biol. 2014; 117:250-263.
23. Zhang C, Liu J, Wang X, Wu R, Lin M, Laddha SV, Yang Q, Chan CS, Feng Z. MicroRNA-339-p inhibits colorectal tumorigenesis through regulation of the MDM2/p3 signaling. ONCOTARGET. 2014; 5:9106-9117.
24. Chen Z, Ma T, Huang C, Hu T, Li J. The pivotal role of microRNA-155 in the control of cancer. J CELL PHYSIOL. 2014; 229:545-550.
25. Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S, Volinia S, Croce CM. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A. 2011; 108:4908-4913.
26. Kopp KL, Ralfkiaer U, Gjerdrum LM, Helvad R, Pedersen IH, Litman T, Jonson L, Hagedorn PH, Krejsgaard T, Gniadecki R, Bonefeld CM, Skov L, Geisler C, Wasik MA, Ralfkiaer E, Odum N, et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. CELL CYCLE. 2013; 12:1939-1947.
27. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J CLIN ONCOL. 2013; 31:2086-2093.
28. Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, Sun S. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. HEPATOLOGY. 2012; 56:1631-1640.
29. Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, Liao Y, Du J. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. EUR J CANCER. 2013; 49:604-615.
30. Zonari E, Pucci F, Saini M, Mazzieri R, Politi LS, Gentner B, Naldini L. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. BLOOD. 2013; 122:243-252.
31. Shi Z, Wei Q, Zhang M, She J. MicroRNAs in Bladder Cancer: Expression Profiles, Biological Functions, Regulation, and Clinical Implications. Crit Rev Eukaryot Gene Expr. 2014; 24:55-75.
32. Pedersen IM, Otero D, Kao E, Miletic AV, Hother C, Ralfkiaer E, Rickert RC, Gronbaek K, David M. OncomiR-55 targets SHIP to promote TNFalpha-dependent growth of B cell lymphomas. EMBO MOL MED. 2009; 1:288-295.
33. Liu F, Kong X, Lv L, Gao J. TGF-beta1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelialmesenchymal transition and cancer stem cell phenotypes. CANCER LETT. 2015; 359:288-298.
34. Ling N, Gu J, Lei Z, Li M, Zhao J, Zhang HT, Li X. microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. ONCOL REP. 2013; 30:2111-2118.
35. Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev. 2001; 15:2934-2939.
36. Inoue K, Mallakin A, Frazier DP. Dmp1 and tumor suppression. ONCOGENE. 2007; 26:4329-4335.
37. Inoue K, Roussel MF, Sherr CJ. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci U S A. 1999; 96:3993-3998.
38. Frazier DP, Kendig RD, Kai F, Maglic D, Sugiyama T, Morgan RL, Fry EA, Lagedrost SJ, Sui G, Inoue K. Dmp1 physically interacts with p53 and positively regulates p53's stability, nuclear localization, and function. CANCER RES. 2012; 72:1740-1750.
39. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. HUM MUTAT. 2003; 21:229-239.
40. Sherr CJ. Divorcing ARF and p53: an unsettled case. NAT REV CANCER. 2006; 6:663-673.
41. Mallakin A, Sugiyama T, Taneja P, Matise LA, Frazier DP, Choudhary M, Hawkins GA, D'Agostino RJ, Willingham MC, Inoue K. Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. CANCER CELL. 2007; 12:381-394.
42. Piantino CB, Reis ST, Viana NI, Silva IA, Morais DR, Antunes AA, Dip N, Srougi M, Leite KR. Prima-1 induces apoptosis in bladder cancer cell lines by activating p53. Clinics (Sao Paulo). 2013; 68:297-303.
43. Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere WR. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLOS ONE. 2013; 8:e61064.
44. Berggren P, Kumar R, Sakano S, Hemminki L, Wada T, Steineck G, Adolfsson J, Larsson P, Norming U, Wijkstrom H, Hemminki K. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. CLIN CANCER RES. 2003; 9:235-242.
45. Zhang C, Liu J, Wang X, Wu R, Lin M, Laddha SV, Yang Q, Chan CS, Feng Z. MicroRNA-339-p inhibits colorectal tumorigenesis through regulation of the MDM2/p3 signaling. ONCOTARGET. 2014; 5:9106-9117.
46. Yarbrough WG, Bessho M, Zanation A, Bisi JE, Xiong Y. Human tumor suppressor ARF impedes S-phase progression independent of p53. CANCER RES. 2002; 62:1171-1177.
47. Tsuji K, Mizumoto K, Sudo H, Kouyama K, Ogata E, Matsuoka M. p53-independent apoptosis is induced by the p19ARF tumor suppressor. Biochem Biophys Res Commun. 2002; 295:621-629.
48. Eymin B, Leduc C, Coll JL, Brambilla E, Gazzeri S. p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. ONCOGENE. 2003; 22:1822-1835.
49. Comprehensive molecular characterization of urothelial bladder carcinoma. NATURE. 2014; 507:315-22.
50. Wilting SM, Snijders PJ, Verlaat W, Jaspers A, van de Wiel MA, van Wieringen WN, Meijer GA, Kenter GG, Yi Y, le Sage C, Agami R, Meijer CJ, Steenbergen RD. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. ONCOGENE. 2013; 32:106-116.
51. Salic A, Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci U S A. 2008; 105:2415-2420.